MA44309A - Oligonucléotides antisens il-34 et leurs procédés d'utilisation - Google Patents

Oligonucléotides antisens il-34 et leurs procédés d'utilisation

Info

Publication number
MA44309A
MA44309A MA044309A MA44309A MA44309A MA 44309 A MA44309 A MA 44309A MA 044309 A MA044309 A MA 044309A MA 44309 A MA44309 A MA 44309A MA 44309 A MA44309 A MA 44309A
Authority
MA
Morocco
Prior art keywords
fibrosis
inflammatory diseases
antisens
oligonucleotides
use methods
Prior art date
Application number
MA044309A
Other languages
English (en)
Inventor
Salvatore Bellinvia
Marie Mcnulty
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MA44309A publication Critical patent/MA44309A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des séquences oligonucléotidiques antisens dirigées contre l'il-34 et des procédés de traitement de maladies inflammatoires, telles que la maladie inflammatoire de l'intestin et / ou la fibrose, associées à une activité ou une expression élevée de l'il-34. L'invention concerne également des compositions pharmaceutiques contenant un oligonucléotide antisens il-34 utile pour traiter les maladies inflammatoires et / ou la fibrose et la fabrication de médicaments contenant un oligonucléotide antisens il-34 décrit à utiliser dans le traitement des maladies inflammatoires et / ou de la fibrose.
MA044309A 2015-11-25 2016-11-25 Oligonucléotides antisens il-34 et leurs procédés d'utilisation MA44309A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260076P 2015-11-25 2015-11-25

Publications (1)

Publication Number Publication Date
MA44309A true MA44309A (fr) 2018-10-03

Family

ID=57471829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044309A MA44309A (fr) 2015-11-25 2016-11-25 Oligonucléotides antisens il-34 et leurs procédés d'utilisation

Country Status (13)

Country Link
US (1) US20180338992A1 (fr)
EP (1) EP3380615B1 (fr)
JP (2) JP2018535681A (fr)
KR (1) KR20180084956A (fr)
CN (1) CN108473989A (fr)
AU (1) AU2016360956A1 (fr)
BR (1) BR112018010736A2 (fr)
CA (1) CA3005932A1 (fr)
ES (1) ES2861516T3 (fr)
MA (1) MA44309A (fr)
MX (1) MX2018006445A (fr)
PT (1) PT3380615T (fr)
WO (1) WO2017089555A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162097B2 (en) * 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
JP2023503804A (ja) * 2019-11-15 2023-02-01 ノグラ ファーマ リミテッド Ｉｌ－３４アンチセンス薬剤、およびこれを使用する方法
WO2022243299A1 (fr) * 2021-05-17 2022-11-24 Nogra Pharma Limited Agents anti-sens il-34 et leurs procédés d'utilisation
JP2024518602A (ja) 2021-05-17 2024-05-01 ノグラ ファーマ リミテッド Ｉｌ－３４アンチセンス剤およびそれを使用する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2242854A4 (fr) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Composés d'arnsi et leurs utilisations
HUE071668T2 (hu) 2008-11-13 2025-09-28 Nogra Pharma Ltd Antiszensz készítmények és eljárások elõállításukra és alkalmazásukra
GB0910833D0 (en) * 2009-06-23 2009-08-05 Univ Edinburgh Avian genes
CA2824843A1 (fr) * 2010-02-04 2011-08-11 Ico Therapeutics Inc. Schemas posologiques permettant de traiter et de prevenir des affections oculaires au moyen d'oligonucleotides c-raf antisens
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP2734547B1 (fr) * 2011-07-18 2016-12-21 The University of Melbourne Utilisation d'antagonistes c-fms
BR112015004426A2 (pt) * 2012-08-31 2018-08-28 Five Prime Therapeutics, Inc. método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
KR20150104275A (ko) * 2014-03-05 2015-09-15 울산대학교 산학협력단 비만 관련 질환의 진단과 치료를 위한 il-34의 용도
EP3169776B1 (fr) * 2014-07-14 2025-09-03 The Regents of The University of California Modulation transcriptionnelle par crispr/cas

Also Published As

Publication number Publication date
JP2021106625A (ja) 2021-07-29
ES2861516T3 (es) 2021-10-06
US20180338992A1 (en) 2018-11-29
BR112018010736A2 (pt) 2018-11-27
WO2017089555A1 (fr) 2017-06-01
AU2016360956A1 (en) 2018-06-07
JP2018535681A (ja) 2018-12-06
CA3005932A1 (fr) 2017-06-01
EP3380615B1 (fr) 2021-01-06
EP3380615A1 (fr) 2018-10-03
KR20180084956A (ko) 2018-07-25
PT3380615T (pt) 2021-04-01
MX2018006445A (es) 2018-08-01
CN108473989A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
GB2419882B (en) Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
WO2009045356A8 (fr) Compositions de micro-arn destinées au traitement de troubles médiés par un vegf
MX2024005653A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
MA43347B1 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
MX385869B (es) Agentes de iarn modificados.
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
MA44309A (fr) Oligonucléotides antisens il-34 et leurs procédés d'utilisation
WO2017019660A8 (fr) Compositions d'arni de xanthine déshydrogénase et leurs méthodes d'utilisation
PE20211393A1 (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
EP1904111A4 (fr) Compositions et procédés pour diminuer l'expression de microarn pour le traitement de la néoplasie
WO2007027761A3 (fr) Utilisation d'antagonistes de l'il-23 et de l'il-17 pour le traitement de la maladie inflammatoire oculaire auto-immune
RU2014101547A (ru) Апоптоз-индуцирующее средство
MX2023008408A (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
WO2019217397A3 (fr) Compositions et méthodes pour améliorer la distorsion de brin
Tehrani et al. Competing endogenous RNAs (CeRNAs): novel network in neurological disorders
MA39145A1 (fr) Dérivés de pipérazine ayant une activité multimode contre la douleur
MY199134A (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis related diseases and respiratory diseases, comprising same
MA38190A3 (fr) Inhibiteurs d'autotaxine
WO2008045576A3 (fr) Compositions et procédés dans lesquels sont utilisés des agents thérapeutiques à base d'arni, destinés au traitement du cancer et d'autres maladies liées à la néovascularisation
MA44836A (fr) Procédés de traitement du syndrome polykystique des reins
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.